First US Patient Enrolls in Phase 2b Study of Therapeutic Vaccine for Lupus
Neovacs announced that it has enrolled the first patient in the United States in its expanded, Phase 2b global clinical trial evaluating IFNalpha-Kinoid, a therapeutic vaccine, to treat systemic lupus erythematosus (SLE). The trial (NCT02665364), which began in September 2015, has attracted the interest of American clinical centers and autoimmune…